WallachBeth Capital Announces Tenon Medical Warrant Inducement for Gross Proceeds of Approximately $2,872,338
Tenon Medical secures a $2.87 million warrant inducement and issues new five-year warrants that could add further capital and dilution.
Rhea-AI Summary
Tenon Medical (TNON) entered into warrant exercise agreements with an institutional investor to immediately exercise outstanding warrants for 572,179 common shares, generating expected gross cash proceeds of approximately $2,872,338.58.
In return, the investor will receive in a private placement new unregistered warrants to purchase up to 858,269 common shares, equal to 150% of the shares issued on exercise of the existing warrants, at an exercise price of $5.02 per share. The new warrants are immediately exercisable and will expire five years from issuance. Closing is expected on or about September 14, 2026, subject to customary conditions. Tenon expects gross proceeds of $2,872,338.58 before advisor fees and expenses, excluding any additional proceeds from future exercises of the new warrants.
Positive
- Gross proceeds of approximately $2,872,338.58 from immediate exercise of 572,179 existing warrants
- Issuance of 858,269 new warrants at $5.02 per share may provide additional future capital
- New warrants are immediately exercisable with a five-year term, enhancing flexibility for future funding
Negative
- New warrants for up to 858,269 shares create potential future dilution for existing shareholders
- Transaction closing remains subject to customary conditions, so proceeds are not yet final
- New warrants and underlying shares are initially unregistered, with liquidity dependent on a future resale registration statement
Details
Market reaction after warrant inducement offering: TNON +15.78%
Following this news, TNON has gained 15.78%, reflecting a significant positive market reaction. Argus tracked a trough of -8.6% from its starting point during tracking. Our momentum scanner has triggered 135 alerts so far, indicating very high trading interest and price volatility. The stock is currently trading at $6.14. Trading volume is exceptionally heavy at 602.9x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Gross proceeds
- $2,872,338.58
- Warrant inducement, before fees and expenses
- Existing warrants exercised
- 572,179 shares
- Immediate exercise in full
- New warrants
- 858,269 shares
- Issued in private placement; equal to 150% of exercised shares
- New warrant exercise price
- $5.02 per share
- Immediately exercisable
- New warrant term
- Five years
- From date of issuance
- Expected closing
- September 14, 2026
- Subject to customary closing conditions
Historical Context
-
Closed related institutional private placement with shares and accompanying warrants
-
Priced related institutional offering with shares and five-year accompanying warrants
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
private placement financial
unregistered warrants financial
resale registration statement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.

The closing of the offering is expected to occur on or about September 14, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds from the warrant inducement are expected to be
WallachBeth Capital is acting as financial advisor for the warrant inducement transaction.
The New Warrants described above were offered in a private placement pursuant to an applicable exemption from the registration requirements of the Securities Act of 1933, as amended (the "Act") and, along with the shares of common stock issuable upon their exercise, have not been registered under the Act, and may not be offered or sold in
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
About WallachBeth Capital LLC:
WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, supporting issuers and investors in achieving their financial goals. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions and ATM's.
Forward-Looking Statements:
This press release contains "forward-looking statements," which are statements related to events, results, activities or developments that Tenon expects, believes or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," and similar expressions and the negative versions thereof. These forward-looking statements, include, but are not limited to, statements regarding the completion of the Offering, the satisfaction of customary closing conditions related to the Offering and the anticipated use of proceeds therefrom. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause Tenon's actual results to be materially different than those expressed in any forward-looking statements, please review Tenon's Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updated from time to time in our Form 10-Q filings and in our other public filings on file with the SEC at www.sec.gov statements contain, particularly the information contained in the section entitled "Risk Factors." We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.
View original content to download multimedia:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-tenon-medical-warrant-inducement-for-gross-proceeds-of-approximately-2-872-338--302876618.html
SOURCE WallachBeth Capital LLC
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What are the main terms of Tenon Medical's new warrants issued in the inducement?
The new warrants allow the holder to purchase up to an aggregate of 858,269 shares of common stock, equal to 150% of the shares issued upon exercise of the existing warrants, at an exercise price of $5.02 per share. They are immediately exercisable on the date of issuance and will expire five years from that date.
When is the warrant inducement transaction expected to close?
The closing of the offering is expected to occur on or about September 14, 2026, subject to the satisfaction of customary closing conditions.
How are the new warrants being offered and what are the transfer restrictions?
The new warrants are being offered in a private placement under an exemption from the registration requirements of the Securities Act of 1933. The warrants and the shares issuable upon their exercise have not been registered under the Act and may not be offered or sold in the United States without registration with the SEC or an applicable exemption.
What role does WallachBeth Capital have in this transaction?
WallachBeth Capital is acting as financial advisor for the warrant inducement transaction.